Vuolteenaho O
Acta Physiol Scand Suppl. 1984;531:1-84.
The qualitative and quantitative aspects of beta-endorphin-related peptides present in the human pituitary gland were investigated using autopsy pituitaries as starting material. Beta-endorphin-related peptides were isolated from two batches of autopsy pituitaries (40 and 51 glands) by acid acetone extraction, acetone precipitation, gel filtration (Sephadex G-75 or Bio Gel P 4/P 10), cation exchange chromatography (SP-Sephadex C-25) and different types of reversed phase high performance liquid chromatography (RP-HPLC). Purification was monitored using beta-endorphin radioimmunoassay, which is specific to the 6-17 sequence of beta-endorphin. Methods suitable for microscale structural analyses of the isolated peptides were developed. Amino acid analysis was performed using quantitative precolumn dansylation and RP-HPLC separation of the dansyl amino-acids. Amino-terminal sequences were determined using semi-microscale manual Edman degradation. An RP-HPLC system was set up for sensitive and unambiguous identification of the released phenylthiohydantoin amino acids. The immunoreactive peptide with the highest apparent molecular weight was identified as human beta-lipotropin on the basis of its amino acid composition. The results of amino-terminal sequence analysis, amino acid compositions of the HPLC-isolated tryptic peptides and carboxy-terminal residue analysis were fully compatible with the previously suggested structure of human beta-lipotropin. About 20% of isolated pituitary beta-lipotropin appeared to be in deamidated form. No proteolytically degraded forms of beta-lipotropin were detected. The yield of pure beta-lipotropin was 6.7-7 nmol/gland. A peptide with properties similar to human beta-endorphin was isolated with a yield of 1.5-5 nmol/gland. Amino acid composition, amino-terminal sequence, carboxy-terminal residue and immunochemical properties were identical to those of human beta-endorphin as suggested previously. About 25% of beta-endorphin appeared to be in methionine sulphoxide form as isolated. Several minor components of immunoreactivity with molecular weight similar to beta-endorphin were detected but none of these were obtained pure even after three RP-HPLC purification steps. Further purification was impossible due to the scarcity of the starting material. A previously unidentified beta-endorphin-related peptide with an apparent molecular weight of about 2000 daltons was isolated from the autopsy pituitaries. Amino acid composition, amino-terminal residue, carboxy-terminal sequence and immunochemical properties showed the peptide to be beta-endorphin 1-18. The yield of isolated peptide was 0.4 nmol/gland. This peptide has not been pr
以尸检垂体为起始材料,对人垂体中存在的β-内啡肽相关肽的定性和定量方面进行了研究。通过酸丙酮提取、丙酮沉淀、凝胶过滤(Sephadex G - 75或Bio Gel P 4/P 10)、阳离子交换色谱(SP - Sephadex C - 25)以及不同类型的反相高效液相色谱(RP - HPLC),从两批尸检垂体(40个和51个腺体)中分离出β-内啡肽相关肽。使用对β-内啡肽6 - 17序列特异的β-内啡肽放射免疫测定法监测纯化过程。开发了适用于对分离出的肽进行微观结构分析的方法。使用定量柱前丹磺酰化和丹磺酰氨基酸的RP - HPLC分离进行氨基酸分析。使用半微量手动埃德曼降解法测定氨基末端序列。建立了一个RP - HPLC系统,用于灵敏且明确地鉴定释放的苯硫代乙内酰脲氨基酸。基于其氨基酸组成,将表观分子量最高的免疫反应性肽鉴定为人β-促脂素。氨基末端序列分析、HPLC分离的胰蛋白酶肽的氨基酸组成以及羧基末端残基分析的结果与先前提出的人β-促脂素结构完全相符。分离出的垂体β-促脂素中约20%似乎处于脱酰胺形式。未检测到β-促脂素的蛋白水解降解形式。纯β-促脂素的产量为6.7 - 7 nmol/腺体。分离出一种性质与人β-内啡肽相似的肽,产量为1.5 - 5 nmol/腺体。氨基酸组成、氨基末端序列、羧基末端残基和免疫化学性质与先前提出的人β-内啡肽相同。分离出的β-内啡肽中约25%似乎处于甲硫氨酸亚砜形式。检测到几种分子量与β-内啡肽相似的免疫反应性次要成分,但即使经过三步RP - HPLC纯化步骤,这些成分也没有得到纯品。由于起始材料稀缺,无法进一步纯化。从尸检垂体中分离出一种先前未鉴定的β-内啡肽相关肽,其表观分子量约为2000道尔顿。氨基酸组成、氨基末端残基、羧基末端序列和免疫化学性质表明该肽为β-内啡肽(1 - 18)。分离出的肽产量为0.4 nmol/腺体。这种肽尚未……